Google
LCTX Stock Price & Analysis — Lineage Cell Therapeutics Inc (Healthcare >> Biotechnology)
LCTX FAQ
What is LCTX's P/E ratio?
Lineage Cell Therapeutics Inc (LCTX) currently trades at a P/E ratio of 325.17.
What is LCTX's ROE?
Lineage Cell Therapeutics Inc reports a Return on Equity (ROE) of -119.18%.
What is LCTX's dividend yield?
Lineage Cell Therapeutics Inc offers a dividend yield of 0.00%.
What is LCTX's Quality Score?
Our AI rates LCTX's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LCTX?
Our AI Timing Score for LCTX is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LCTX belong to?
Lineage Cell Therapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange
LCTX AI Analysis Summary
Our AI summary for LCTX: Lineage Cell Therapeutics Inc (NYSE MKT), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 325.17, ROE of -119.18%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.12
Price
0.02
(1.79%)
Day Change
|
|
|---|
LCTX, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.12 |
| PBV / Sector |
5.25 / 44,022.72
|
| Earning Per Share | -0.26 |
| PE / Sector |
325.17 / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
1.06 M
GREAT
|
| Average 1W Daily Value |
0.87 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
62% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-05 08:00:28 |
| Symbol | LCTX |
| Name | LINEAGE CELL THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE MKT |
| Listed Shares | 249.30 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 276.72 / 9,586.08 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2173 Salk Avenue, Carlsbad, CA, United States, 92008
Phone: 442 287 8990
Website: https://www.lineagecell.com
Employees: 72
Sector: Healthcare >> Biotechnology
Description: Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap